Related Experiment Videos
A dynamic population model of disease progression in COPD
M Hoogendoorn1, M P M H Rutten-van Mölken, R T Hoogenveen
1Institute for Medical Technology Assessment (iMTA), Erasmus MC, P.O. Box 1738, 3000 DR Rotterdam, The Netherlands. e.hoogendoorn@erasmusmc.nl
The European Respiratory Journal
|August 2, 2005
Summary
A dynamic model of Chronic Obstructive Pulmonary Disease (COPD) in the Netherlands projects disease progression and costs. Smoking cessation interventions were found to be cost-effective, with minimal counseling yielding net savings.
Area of Science:
- Pulmonary Medicine
- Health Economics
- Epidemiology
Background:
- Chronic Obstructive Pulmonary Disease (COPD) poses a significant public health challenge.
- Accurate modeling is crucial for understanding disease burden and informing policy.
Purpose of the Study:
- To develop a dynamic population model for Chronic Obstructive Pulmonary Disease (COPD) in the Netherlands.
- To project COPD incidence, prevalence, mortality, progression, and costs from 2000-2025.
- To evaluate the cost-effectiveness of smoking cessation interventions for COPD patients.
Main Methods:
- A dynamic Dutch population model was created, incorporating population dynamics and smoking prevalence.
- Disease progression was modeled based on forced expiratory volume in one second (FEV1) decline.
- Projections compared current practices with scenarios involving smoking cessation counseling (minimal and intensive with bupropion).
Main Results:
- COPD prevalence is projected to increase between 2000-2025 across all severity stages.
- Costs per inhabitant are also projected to rise for all COPD severity levels.
- Both smoking cessation scenarios demonstrated cost-effectiveness, with minimal counseling resulting in net savings.
Conclusions:
- The developed COPD progression model provides valuable insights into the future disease burden.
- The model can effectively assess the long-term impact of interventions on COPD.
- Smoking cessation interventions are crucial and cost-effective for managing COPD.